Intensive lipid intervention in the post-ENHANCE era.
O'Keefe
James H
JH
Bybee
Kevin A
KA
Lavie
Carl J
CJ
D000924:Anticholesteremic Agents / Q000008:administration & dosage*; D000069059:Atorvastatin; D001384:Azetidines / Q000008:administration & dosage; D003327:Coronary Disease / Q000517:prevention & control*; D048909:Diabetes Complications / Q000188:drug therapy; D018450:Disease Progression; D004359:Drug Therapy, Combination; D000069438:Ezetimibe; D005464:Fluorobenzenes / Q000008:administration & dosage; D006538:Heptanoic Acids / Q000008:administration & dosage*; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000188:drug therapy*; D007676:Kidney Failure, Chronic / Q000150:complications; D017410:Practice Guidelines as Topic; D011743:Pyrimidines / Q000008:administration & dosage; D011758:Pyrroles / Q000008:administration & dosage*; D016032:Randomized Controlled Trials as Topic; D000068718:Rosuvastatin Calcium; D019821:Simvastatin / Q000008:administration & dosage; D013449:Sulfonamides / Q000008:administration & dosage
D000924:Anticholesteremic Agents; D001384:Azetidines; D005464:Fluorobenzenes; D006538:Heptanoic Acids; D011743:Pyrimidines; D011758:Pyrroles; D013449:Sulfonamides; D000068718:Rosuvastatin Calcium; D000069059:Atorvastatin; D019821:Simvastatin; D000069438:Ezetimibe